Rimegepant clinical trials
Also written BHV-3000 and Nurtec ODT.
How each study uses rimegepant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rimegepant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Feb 2020 · NURTEC ODT · NDA 212728 (FDA, Drugs@FDA)
- European Union
- 25 Apr 2022 · Vydura · EMEA/H/C/005725 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2026 (12)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 11 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 6 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 19
Pfizer (27) · Mayo Clinic (3) · Second Affiliated Hospital, School of Medicine, Zhejiang University (2) · Antonios Likourezos (2) · Weill Medical College of Cornell University (1) · Chinese PLA General Hospital (1) · Shanghai Zhongshan Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
Often tested with
Tested in the same studies.
Zavegepant (2) · Aspirin (1) · Ketamine (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Gemcitabine (1) · Immune checkpoint inhibitors (1) · Rizatriptan (1)
Related medicines
As reviewed, each with the page that says it.
- One of CGRP receptor antagonists source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test rimegepant, phase 3 first.
- Nov 2026A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigrainePhase 3 · Pfizer
- Feb 2027Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard TherapyPhase 1 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Jun 2027A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare ProfessionalsNot applicable · Chinese PLA General Hospital
- Jul 2027A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency DepartmentPhase 1 · University of South Florida
Studies
Open first, then newest update. How each study uses rimegepant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 46
- A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare ProfessionalsNot yet recruitingNot applicableChinese PLA General HospitalNCT07918053Written as Rimegepant 75 mg ODT
- Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of MigraineRecruitingPhase 3PfizerNCT04743141Written as Rimegepant (PF-07899801)
- Randomized Study in Children and Adolescents With Migraine: Acute TreatmentRecruitingPhase 3PfizerNCT04649242Written as Rimegepant/BHV3000
- A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency DepartmentRecruitingPhase 1University of South FloridaNCT07667621Written as Rimegepant
- A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in IndiaRecruitingPhase 4PfizerNCT07685769Written as Rimegepant 75 mg ODT
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsRecruitingPhase 3PfizerNCT05156398Written as Rimegepant
- A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic MigraineRecruitingPhase 3PfizerNCT07729462Written as Rimegepant
- A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With MigraineRecruitingPhase 4PfizerNCT07609914Written as Rimegepant
- A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine HeadacheRecruitingPhase 4Antonios LikourezosNCT06473597Written as Rimegepant
- Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard TherapyRecruitingPhase 1Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07835035Written as Rimegepant
- Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell CarcinomaNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07812467Written as Rimegepant
- Rimegepant For Endometriosis PainNot yet recruitingPhase 2Mayo ClinicNCT07795125Written as Rimegepant 75 MG
- A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority StudyNot yet recruitingPhase 2Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07751497Written as Rimegepant
- A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigraineRecruitingPhase 3PfizerNCT06641466Written as Rimegepant
- Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCLNot yet recruitingPhase 2Ruijin HospitalNCT07613788Written as Rimegepant
- Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingPhase 1/2Xiuchao WangNCT07475234Written as Rimegepant plus Nab-Paclitaxel and Gemcitabine
- Efficacy and Safety of Rimegepant for Acute DizzinessNot yet recruitingPhase 2/3Shi TianmingNCT07435090Written as Rimegepant 75mg Orally Disintegrating Tablets (ODT)
- Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the USRecruitingPhase 4Medstar Health Research InstituteNCT07301008Written as Rimegepant 75 MG
- Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer PatientsNot yet recruitingPhase 2Fudan UniversityNCT06999252Written as Rimegepant
- A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experimentNot yet recruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06748664Written as Rimegepant
See all 46 studies that test rimegepant →
As the comparator · 2 — what is tested is compared with rimegepant
- Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of MigraineTerminatedPhase 4Danish Headache CenterNCT05211154Written as Rimegepant 75 MG
- A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic MigraineCompletedPhase 4Eli Lilly and CompanyNCT05127486Written as Rimegepant
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting1
Newly registered1
Codes
What other systems call rimegepant · ClinicalTrials.gg INT006230
- MeSH (NLM) C578443rimegepant sulfateConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 997WVV895XRIMEGEPANTConfirmed FDA, Wikidata
- RxNorm 2282307One source FDA
- Wikidata Q27272184rimegepantConfirmed FDA, Wikidata
- NCI Thesaurus C152220RimegepantOne source FDA
- DrugBank DB12457One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C578443 | rimegepant sulfate | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 997WVV895X | RIMEGEPANT | Confirmed FDA, Wikidata |
| RxNorm | 2282307 | — | One source FDA |
| Wikidata | Q27272184 | rimegepant | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152220 | Rimegepant | One source FDA |
| DrugBank | DB12457 | — | One source Wikidata |
Also registered as rimegepant sulfate (UNII 1383NM3Q0H · RxNorm 2282322).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.